immunocore-logo-2018
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference
23 nov. 2022 07h00 HE | Immunocore Holdings Limited
Immunocore to present at the 5th Annual Evercore ISI HealthCONx Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 23 November 2022) Immunocore Holdings Plc...
immunocore-logo-2018
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
11 nov. 2022 09h00 HE | Immunocore Holdings Limited
Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting Expression of gp100 protein, the target of KIMMTRAK, is...
DBMR Logo.png
Melanoma Market Is Likely to Upsurge USD 13.11 Billion with Excellent CAGR Of 11.8% by 2029, Size, Share, Trend, Demand, Challenges and Competitors Outlook
17 oct. 2022 11h29 HE | Data Bridge Market Research
BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Data Bridge Market research has a newly released expansive study titled “Melanoma Market” which guarantees you will remain better informed than your...
Derm-Biome-Pharmaceuticals.png
Derm-Biome Pharmaceuticals, Inc. reports positive preclinical data in melanoma and squamous cell carcinoma, initiates a program aimed at advancing topical therapies for skin cancer to the clinic
12 oct. 2022 10h00 HE | Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based preclinical biopharmaceutical company focused on skin health and healthy aging, has...
Lyell_Branding_Color_RGB_102918a copy.jpg
Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors
06 oct. 2022 16h05 HE | Lyell Immunopharma, Inc
Autologous TIL therapy enhanced with Lyell’s Epi-R™ reprogramming technology designed to create polyclonal T cell populations with properties of durable stemness and improved functionPhase 1 trial to...
ADCS Logo.jpg.jpeg
Advanced Dermatology and Cosmetic Surgery Provides Breast Cancer Patients and Survivors with Free Skin Cancer Screenings for Breast Cancer Awareness Month
20 sept. 2022 09h00 HE | Advanced Dermatology and Cosmetic Surgery
MAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, Advanced Dermatology and Cosmetic Surgery announces it will offer complimentary skin cancer screenings...
Discovery of Bispecific Antibodies and Immune Checkpoint Inhibitors That Kill Glioblastoma Cells and Melanoma Cells, and Block the Metastasis of Malignant Melanoma Cells to the Lung by Over 90%, Announced by Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA)
06 sept. 2022 07h59 HE | Ocean Biomedical, Inc.
Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., expected to be listed on NASDAQ under the symbol, “OCEA”....
Press release Biocartis Group NV: Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma Patients
01 sept. 2022 01h01 HE | Biocartis NV
PRESS RELEASE: 1 September 2022, 07:01 CEST Biocartis Initiates Commercialization in Europe of SkylineDx’s Innovative Merlin™ Assay (CE-IVD) for Melanoma PatientsMerlin helps identify melanoma...
Persbericht Biocartis Group NV: Biocartis start commercialisatie in Europa van SkylineDx’s innovatieve Merlin™ Assay (CE-IVD) voor melanoma patiënten
01 sept. 2022 01h01 HE | Biocartis NV
PERSBERICHT: 1 september 2022, 07:01 CEST Biocartis start commercialisatie in Europa van SkylineDx’s innovatieve Merlin™ Assay (CE-IVD) voor melanoma patiëntenMerlin helpt melanoompatiënten te...
AIMLogo.jpg
AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma
30 août 2022 07h30 HE | AIM ImmunoTech Inc.
Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma First patient dosing is expected in Q4, 2022 OCALA,...